Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Outsourcing
C2 Pharma boosts digoxin business
by Michael McCoy
March 22, 2019
| A version of this story appeared in
Volume 97, Issue 12
Credit: Shutterstock
Digoxin is extracted from the leaves of Digitalis lanata, also called foxglove.
C2 Pharma, a supplier of niche active pharmaceutical ingredients (APIs), has acquired the digoxin API business of the Polish firm Nobilus Ent. C2 says the purchase complements production of digoxin that the Indian firm Laurus Labs conducts on its behalf. Digoxin is a plant extract used to treat heart conditions. C2 says it is responding to supply inconsistency due to high impurity levels and an unreliable supply chain.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter